When was Neuraly founded?

Neuraly was founded in 2016 and raised its 1st funding round within a year of its incorporation.

Where is Neuraly located?

Neuraly is headquartered in Germantown, United States. It is registered at 704 Quince Orchard Rd, Suite 320 Gaithersburg, MD 20878.

Who is the current CEO of Neuraly?

Seulki Lee of Neuraly. They have also founded 1 company.

How many employees does Neuraly have?

As of Jun 30, 2026, the latest employee count at Neuraly is 17.

Is Neuraly a funded company?

Neuraly is a funded company, having raised a total of $36M across 2 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on Dec 22, 2016.

When was the latest funding round of Neuraly?

Neuraly's latest funding was a $***** Series A round on Jul 18, 2018, with participation from 9 investors.

Where does Neuraly rank among its competitors?

Neuraly ranks 52nd amongst 457 active competitors, of which 161 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Alchemab, which secured $34M in Jul, 2026.

Who are the top competitors of Neuraly?

Neuraly's top competitors include Denali Therapeutics, Fulcrum Therapeutics and Regenxbio. Among them, Alchemab secured the most recent funding round in July, 2026.

Neuraly - 2026 Company Profile, Team, Funding & Competitors

Neuraly is a series A company based in Germantown (United States), founded in 2016 by Seulki Lee. It operates as a Pioneering neurodegenerative disease treatments, offering hope for Alzheimer's and Parkinson's. Neuraly has raised $36M in funding. The company has 457 active competitors, including 161 funded and 82 that have exited. Its top competitors include companies like Denali Therapeutics, Fulcrum Therapeutics and Regenxbio.

Company Details

Pioneering neurodegenerative disease treatments, offering hope for Alzheimer's and Parkinson's. The company is dedicated to discovering and developing revolutionary therapies for neurodegenerative diseases, focusing on innovative approaches to address conditions like Alzheimer's and Parkinson's. They are developing drugs that target new pathways, leveraging scientific innovation to deliver medicines with the potential to change lives. Their clinical development strategy centers on inhibiting pathological glial activation to prevent neuronal cell death. With a world-class team of innovators, they are committed to finding cures where disease-modifying therapies are lacking. The company's mission is to develop innovative treatments to help people live better, fuller, and longer lives, striving to be a respected leader in the discovery and development of breakthrough medicines. Their core values include pioneering spirit, science-driven decisions, integrity, and collaboration.

Website: www.neuralymed.com/
Email ID: *****@neuralymed.com
Phone Number: +1 **********
Part Of
Registered Address: 704 Quince Orchard Rd, Suite 320 Gaithersburg, MD 20878

Key Metrics

Founded Year

2016

Location

Germantown, United States

Stage

Series A

Total Funding

$36M in 2 rounds

Latest Funding Round

Series A, Jul 18, 2018, $*****

Investors

Octave Ventures & 10 more

Ranked

52^nd among 457 active competitors

Employee Count

17 as on Jun 30, 2026

Similar Companies

Denali Therapeutics & 567 more

View Neuraly's full profile

Neuraly is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Neuraly Inc. CIN: 46-1382575 , United States, Active	Jul 07, 2016	-	42 (As on Dec 31, 2020)	-

Neuraly has raised a total funding of $36M over 2 rounds. Its first funding round was on Dec 22, 2016. Its latest funding round was a Series A round on Jul 18, 2018 for $*****. 9 investors participated in its latest round. Neuraly has 11 institutional investors.

Here is the list of recent funding rounds of Neuraly:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 18, 2018	3861751	Series A	2419523	1007738	8640212	3784459
Dec 22, 2016	1693794	Conventional Debt	2723424	7967321	3407953	2186863

Access funding benchmarks and valuations. Sign up today!

View details of Neuraly's funding rounds and investors

The founders of Neuraly is Seulki Lee. Seulki Lee is the CEO of Neuraly.

Here are the details of Neuraly's key team members:

Seulki Lee: Co-Founder & CEO of Neuraly.
Contact Info: 1 email address

View details of Neuraly's Founder profiles and Board Members

Neuraly's employee count trend

Neuraly has 17 employees as of Jun 26. Here is Neuraly's employee count trend over the years:

Uncover Neuraly's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Neuraly include Denali Therapeutics, Fulcrum Therapeutics and Regenxbio. Here is the list of Top 10 competitors of Neuraly, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Foresite Capital, Google Ventures & 10 others	72/100
2nd	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	71/100
3rd	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
4th	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Redmile Group, New Enterprise Associates ... & 17 others	67/100
5th	Mission Therapeutics 2011, Cambridge (United Kingdom), Series D	Developer of small molecule inhibitors targeting specific disease associated enzymes	$192M	Sofinnova Partners, Pfizer Venture Investments ... & 46 others	66/100
6th	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	65/100
7th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Perceptive Advisors, Sanofi & 5 others	65/100
8th	Athira Pharma 2011, Seattle (United States), Public	Developer of drugs for neurodegenerative diseases	$121M	Dolby Family Ventures, Alzheimer's Drug Discovery ... & 22 others	65/100
9th	Alchemab 2019, London (United Kingdom), Series A	Developer of antibody therapeutics for treating oncology and neurodegenerative conditions	$149M	RA Capital Management, SV Health Investors ... & 14 others	64/100
10th	D&D Pharmatech 2014, Seongnam-si (South Korea), Public	Developer of GLP-1-based therapeutics for metabolic disease treatment	$205M	Smile Gate Investment, Praxis Capital & 10 others	64/100
52nd	Neuraly 2016, Germantown (United States), Series A	Pioneering neurodegenerative disease treatments, offering hope for Alzheimer's and Parkinson's	$36M	Octave Ventures, Smile Gate Investment & 9 others	54/100